As of November 6, 2026, Novo Nordisk A/S (NVO) trades at $40.31. No model fair value is published for NVO. NVO reports its financial statements in DKK. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar.
Source: Equity Rank — NVO valuation (data as of 2026-11-06). The full page shows the company’s fundamental profile and earnings data.
Reported EPS came in above the analyst estimate in 6 of the last 8 reports. The median share-price change across a report, in either direction, was 2.6%.
| Report | EPS estimate | EPS actual | vs estimate | Price change |
|---|---|---|---|---|
| Nov 4, 2026 | $0.81 | $5.79 | +614.8% | +5.0% |
| Aug 5, 2026 | $0.82 | $0.96 | +17.1% | +3.2% |
| May 6, 2026 | $6.96 | $6.63 | -4.7% | +0.1% |
| Feb 3, 2026 | $5.90 | $6.04 | +2.4% | -6.2% |
| Nov 5, 2025 | $0.77 | $1.02 | +32.5% | +0.4% |
| Aug 6, 2025 | $6.00 | $5.96 | -0.7% | -3.9% |
| May 7, 2025 | $6.07 | $6.53 | +7.6% | +1.9% |
| Feb 5, 2025 | $5.97 | $6.34 | +6.2% | +1.7% |
Equity Rank's fundamental strength composite scores NVO at 73.6/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at -23.3% per year and gross margin has moved -2.9 pp. Its SAVE composite score has moved +1.9 over the past 30 days.
NVO reports its financial statements in DKK. Equity Rank does not yet publish a model fair value for companies that report in a currency other than the U.S. dollar. Informational only — not investment advice.
Novo Nordisk A/S (NVO) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.
Novo Nordisk A/S (NVO) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
More on NVO: If you had invested $1,000 in NVO
All General Drug Manufacturers stocks with model fair values
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks
Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/NVO. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of November 6, 2026 and are recomputed after every U.S. market close.